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Summary 
Recombinant full-length human CD23  has been incorporated into fluorescent liposomes to 
demonstrate the existence of a ligand for CD23 that is different from the previously known 
ligand, immunoglobnlin E (IgE). The novel ligand for CD23 is expressed on subsets of normal 
T cells and B ceUs as well as on some myeloma ceU lines. The interaction of full-length CD23 
with its ligand is specifically inhibited by anti-CD23 monodonal antibodies and by IgE, and 
it is Ca  z+  dependent. Moreover,  tunicamycin treatment of a CD23-binding cell line, RPMI 
8226,  significantly reduced the binding of CD23 incorporated into fluorescent liposomes, and 
a sugar, fucose-l-phosphate, was found to inhibit CD23-liposome binding to RPMI 8226 cells, 
suggesting the contribution of sugar structures on the CD23 ligand. In addition, CD23-transfected 
COS cells were shown to form specific conjugates with the cell line RPMI 8226.  These data 
demonstrate that CD23 interacts with a ligand, which is different from IgE, and that CD23 
can be considered as a new surface adhesion mohcule involved in cell-cell interactions. 
C 
D23 is a type II transmembrane protein expressed on 
a wide variety of hemopoietic cell types (1-3).  CD23 
exists  in  two forms, a  and  b,  differing within  their  in- 
tracytoplasmic domains. The a form is expressed exclusively 
on B lymphocytes, whereas the b form is expressed on both 
B cells and other cell types (4). 
Studies using anti-CD23 antibodies and soluble CD23 frag- 
ments have implicated this molecule in the regulation of IgE 
synthesis (5, 6). Membrane CD23 has been shown to mediate 
IgE-dependent antigen focusing (7). 
An increasing number of reports have demonstrated that 
CD23 also plays a role in non-IgE-related activities  such as 
B cell growth (8,  9),  germinal center B cell survival  (10), 
prothymocyte maturation (11), myeloid precursor prolifera- 
tion (12), and antigen presentation (13). This latter observa- 
tion, together with the earlier finding that CD23 was spa- 
tially associated with the MHC class II molecule HLA-DR 
on the B cell surface (14), suggested that CD23 may be in- 
volved in T ceU-B cell interactions. Indeed, we recently found 
that certain anti-CD23 antibodies blocked T cell-B cell con- 
jugate formation in vitro (J. Shields, J.-P. Aubry, D. Estoppey, 
and J.-Y. Bonnefoy, manuscript submitted for publication). 
These findings led us to investigate if CD23 interacts with 
a membrane structure that is different from IgE, the only 
known CD23 ligand (15, 16). Using recombinant CD23 in- 
corporated into  fluorescent liposomes, the  present  study 
demonstrates the  existence  of a  membrane-bound ligand 
for CD23. 
Materials and Methods 
Cell Lines 
The B cell  lines  Daudi, ILPM18226,  U266-B1, and IM-9, Jijoye; 
the T cell  lines  Molt-4 and Hut 78; the promyelomonocytic cell 
line  HL-60; the  histiocytic  lymphoma cell  line  U-937; the  chronic 
myelogenous leukemia K-562; the astrocytoma cell  line  U-373; 
and the epidermoid carcinoma Hep-2 were all  obtained  from the 
American  Type Culture Collection (ATCC), Kockville,  MD. The 
T cell line Jurkat was provided by Dr. A. Bernard (H6pitai de 
l'Archet, Nice, France). The B cell lymphoma HFB1 was obtained 
from Dr. K. Callard (University of London, London, UK) and 
was transfected with CD23 full-length cDNA (a gift of Dr. H. 
Kikutani, Osaka University, Osaka, Japan) giving HFB12/3 (17). 
COS-CD23 transfectants were obtained by subcloning the CD23 
cDNA into the pCDM8 expression  vector (Invitrogen, San Diego, 
CA) and transfecting the resulting expression vector into COS 
M6 ceils (a gift of Dr. I. Stamenkovic,  Massachusetts  General  Hos- 
pital, Boston, MA) using DEAl/dextran as previously described 
(18). The Burkitt lymphoma cell line BL2 was obtained from Dr. 
G. Lenoir (International Agency for Kesearch on Cancer, Lyon, 
France). The myeloma cell line U266 was obtained from Dr. J. P. 
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lymphobhstoid line RPM18866 was obtained from Dr. K. Ishizaka 
(Johns Hopkins University School of Medicine, Baltimore, MD). 
Cell lines were cultured in RPMI 1640 (Seromed, Berlin, Ger- 
many) supplemented with 2 mM glutamine  and  10%  heat-in- 
activated FCS (Flow Laboratories, Irvine, Scotland). An cell lines 
were mycoplasma free. Tonsil mononuclear cells were separated 
into T  and  B cell subpopulations  (referred to as E + and  E-, 
respectively) by rnsetting with AET-treated sheep red blood calls. 
The germinal center B cells (GCC) were enriched according to 
the method ofLiu et al. (19) with the ,clcled  modifications  of  Graber 
et al. (20). Human umbilical vein endothelial cens (HUVEC) were 
prepared as previously reported (21). For tunicamycin treatment, 
B cell lines IM-9 and RPMI 8226 were cultured 48 h in complete 
medium containing 0.8 #g/ml of tunicamycin (Boehringer Mann- 
heim, Mannheim, Germany). The binding of CD23 liposomes and 
control liposomes was compared on tumicamyein-treated and non- 
treated cells by flow cytometric analysis. 
mAbs 
Anti-CD23 mAbs were kindly provided  by P. Beverley  (22) (LA1, 
IgM), by Dr. R Sugden (23) (EBVCS 1, IgG1), and by Dr. J. Gordon 
(MHM6, IgG1). The anti-CD23 mAb 25 (16) (IOB8, IgG1) was 
purchased  from  Immunotech  (Luminy, France). The  isotype- 
matched controls, IgG1, and IgM were purchased from Becton Dick- 
inson  &  Co.  (Mountain  View, CA).  Sheep FITC-conjugated 
(Fab')2 antibodies to mouse  IgG and  IgM were obtained  from 
Grub (Vienna, Austria). Human IgE myeloma  protein (The Binding 
Site Ltd., Birmingham,  UK) was purified as previously described 
(24). The polyclonal antibody Rb55 was obtained by immuniza- 
tion of  a rabbit with a CD23 fragment (amino acid position 150-321 
of the CD23 sequence) expressed in Escherickia coli. 
Recombinant Full-Length CD23 Purification 
The 45-kD CD23 a form was obtained from SD cell cultures 
infected with the recombinant baculovirus clone B1 as already de- 
scribed (9). 10  I~ cells were harvested 3 d postinfection by gentle 
centrifugation  of 1,000 g  for 15  min.  The pelleted cells were 
resuspended in 50 ml of  buffer A: 10 mM Tris-HC1, 1 mM TLCK, 
1 mM benzamidine, I mM PMSF, 10 mM iodoacetamide, pH 7.8, 
and broken by two passages through an Amicon French pressure 
cell (Kontron, Basel, Switzerland). The suspension was sonicated, 
diluted twofold in buffer B: 0.1 M NaC1, 1 mM CaCI~, 1 mM 
MgClz, and 0.5 M sucrose, added to buffer A, and centrifuged at 
22,500g for 30 min. The pellet was resuspended in buffer C: 1 mM 
CaClz,  1 mM MgCI2 in PBS240 (240 mM NaC1, 3 mM KCI, 
8 mM NazHPO4, 1.5 mM KHzPO4, 0.2 mM TLCK, 10 mM io- 
doacetamide, pH 7.1), mixed with an equal volume of absolute 
ethanol at  -200C, agitated, and incubated 30 rain at room tem- 
perature. The ethanol precipitate was then centrifuged 10 rain at 
3,000 g. The membranes were resuspended in 25 ml of buffer C, 
ethanol precipitated a second time, and redissolved in buffer D: 
1% Triton X-100 in PBS~. The detergent extract was incubated 
overnight at 40C and centrifuged at 150,000 g for 60 min. The 
solubilized material was immunoporified on a mAb 25-Afftgel 10 
column (Bio-Rad Laboratories  A.G., Glatthrngg, Switzerland) with 
3 mg mAb 25 coupled per ml resin at 5 ml/h with constant recy- 
cling for 24 h. The immunoaffmity resin was washed with 200 
ml buffer D followed by a 200 ml of buffer E: 0.1% Triton X-100 
in PBSu0. In the third wash (200 ml), Triton X-100 detergent in 
buffer  E  was  exchanged  by  50  mM  octyl-/3-glucopyranoside 
(OGP)  I and 45-kD CD23 was eluted with 50 rrd PBS (140 mM 
NaC1, 3 mM KC1, 8 mM NazHPO4, 1.5 mM KH:~PO4, pH 7.1), 
50 rnM OGP, 3 M NH4SCN, pH 6.5. The protein was desalted 
on a Superdex-200  XK16/60 gel filtration column (Pharmacia, Upp- 
sah,  Sweden) run in PBS, 50 mM OGP. 
Densitometric scanning of silver-stained  SDS-PAGE  and Western 
blotting analysis of the proteins transferred onto a nitrocellulose 
membrane  were used throughout the procedure  to follow the 
purification as already described (20), except that the membrane 
was immunostained with the polydonal antibody Rb55. 
Liposome Preparation 
10/zmol of the synthetic phospholipids POPC (Avanti Polar- 
lipids Inc., Alabaster, AL) in CHC13 were mixed with 50 nmol 
of the fluorescent label DiOls  (Molecular Probes Inc.,  Eugene, 
OIL) in EtOH. The solvents were evaporated under a nitrogen 
stream and the lipids were further dried in a vacuum centrifuge 
for 30 min. The dried lipids were then completely solubilized in 
50 t~l of 800 mM OGP in PBS. The detergent concentration was 
lowered to 200 mM with 150/zl of PBS and 0.2 nmol of the pro- 
tein (CD23 or glycophorin A [Calbiochem, Lucerne, Switzerland] 
as control) was added in 800/~1 of 50 mM OGP in PBS, at 4"C. 
The mixture was incubated 1 h at 4~  filtered through a sterile 
0.2/zm Acrodisc 13 (Gelman Sciences, Ann Arbor, MI), and ex- 
tensively dialyzed in a Spectra/Pot membrane (Spectrum Medical 
Industries, Inc., Los Angeles, CA) (molecular mass cut-off, 12-14 
x  I(P kD; dry thickness, 0.0011 in) against several  changes of 140 
mM NaC1, 20 mM Hepes, pH 7, for 48 h. 
Control liposomes were prepared in the same way except that 
there was no protein added. Fluorescent liposomes were then ready 
for flow cytometric studies. 
Flow Cytometric Analysis 
Liposome Binding Assays.  Cells (10  s) were resuspended in 50 
/~1 of the liposome suspension diluted 10 times (or 40 times in the 
experiments with tunicamycin) in 0.5% BSA, 0.1% azide, 2 mM 
CaC12, 140 mM NaC1, 20 mM Hepes, pH 7, and incubated for 
2 h at 4~  Cells were washed twice before analysis. 
Inhibition with sugars: glucose, gahctose, mannose, cellobiose, 
lactose, mannobiose, N, N'-diacetykhitobiose, glucose-l-phosphate, 
and fucose-l-phosphate (all from Sigma Chemical Co., St. Louis, 
MO) have been tested between 0.02 and 50 mM in the buffer men- 
tioned above, for their ability to prevent CD23-liposomes from 
binding  to RPMI 8226 for 2 h at 4~ 
Conjugate Formation.  COS cells  or RPM18226 and Molt-4 were 
labeled with BCECF-AM at 10 ng/ml and Indo-l-AM at 1/zg/ml, 
respectively (both from Calbiochem), for 35 rain at 370C, washed 
three times, and resuspended at 5  x  10S/ml. Equal volumes of 
COS cells and RPMI 8226 or Molt-4 cells (0.5 ml at 5 x  10S/m1) 
were mixed, centrifuged at 120 g for 5 min at room temperature, 
then incubated at 370C in a waterbath for 10 rain. Cells were gently 
resuspended by inversion and analyzed on a FACStar Plus  |  (Becton 
Dickinson & Co., Erembodeggen, Belgium). Parameter settings 
and compensation were set on the instrument using a single popu- 
lation of labeled ceils before conjugate analysis. Conjugates were 
defined as those events that registered a positive signal for both 
Indo-1 and BCECE A minimum of 10,000 events were analyzed 
for each set of conjugates. 
1  Abbreviations  used in thispaper:  MFI, mean fluorescence  intensity; OGP, 
octyl-/3-glucopyranoside. 
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tibody were added to COS cells for 30 min at 4~  followed by 
one wash before conjugates were formed as described above. 
Results 
Recombinant CD23 Incorporated into Fluorescent Liposomes 
Bind to Some T Cells and B Cells.  To search for a ligand for 
CD23  that is  different from IgE,  recombinant full-length 
CD23  was  incorporated  into  fluorescent  liposomes.  The 
recombinant membrane form of CD23 was expressed in in- 
sect cells using the baculovirus expression system (9),  and 
purified to homogeneity  by immunoatiinity chromatography, 
resulting in a preparation that was 95% pure (Fig.  1 A) as 
assessed by coomassie blue-stained SDS-PAGE  and Western 
blotting  analysis  (Fig.  1 B). 
This material, or glycophorin as control, was then recon- 
stituted into artificial membranes, and the presence and ac- 
cessibility of the protein was demonstrated by double fluores- 
cence analysis or dot-blot immunostaining using the respective 
antibody (data not shown). Light scattering experiments were 
performed to analyze the vesicles'  size distribution,  which 
was found homogenous and devoid of aggregates. The mean 
diameter of CD23 liposomes and liposomes containing no 
protein was ~150  nm (data not shown). 
Flow cytometric analyses of different cell types were per- 
formed after incubation of the cells with the CD23-incor- 
porated fluorescent liposomes or control liposomes (Table 1). 
As predicted from some of the reported biological activities 
of soluble CD23 in vitro, germinal center B cells as well as 
a subpopulation of T  cells bound to CD23  liposomes.  In- 
terestingly, two myeloma  cell lines, U266-B1 and RPM18226, 
were the most positive cell lines.  Variations in the intensity 
of the staining (related to  the mean fluorescence intensity 
[MFI]) obtained with CD23 liposomes were observed, ac- 
cording to the growth phase of the cells (data not shown). 
Figure 1.  SDS-PAGE  and Western  blotting  analysis  of  full-length  CD23 
e~pressed  in insect cells. Aliquots from different  steps of the purification 
were subjected  to dectrophoresis  on a 15% (wt/vol) polyacrylamide  gel 
and stained  with coomassie  blue  (A) or transferred  onto  nitrocellulose  mem- 
brane and immunostained  with gb55 (B). Lanes  a, prestained  molecular 
mass standards (kD) (Bio-Rad Laboratories); lanes b, ~tract of recom- 
binant SD cells; lanes  c, membranes  after ethanol precipitation; lanes  d, 
detergent  extract  of  membranes;  lanes  e, mAb 25 immunoaifinity  elution; 
lanes  f, Superdex-200  final pool. 
The ILPM18226 cell line was mainly used for further studies. 
EBV-transformed B  cell lines were either slightly positive 
(1LPMI 8866,  IM-9) or negative (Dandi).  Cell lines of the 
macrophage type (U-937 and HL-60)  were negative. In all 
cases, negligible binding was observed with liposomes that 
did not contain protein compared with calls alone. The cell 
lines that bound most CD23  liposomes,  ILPMI 8226  and 
U266-B1,  did not bind the glycophorin-containing liposomes. 
Taken together, these data strongly suggest the existence of 
a ligand for CD23 on B cell and T cell subsets. Further studies 
using anti-CD23  antibodies support  this conclusion. 
The Binding of CD23 to Its Ligand Is Specifically Inhibited 
by Anti-CD23 mAbs and Is Ca  2+ Dependent.  To show the 
specificity of the interaction of CD23 with its ligand, anti- 
bodies to CD23 were tested for their capacity to inhibit the 
binding of CD23 liposomes to the RPMI 8226 cell line. As 
shown in Fig.  2,  all the anti-CD23  antibodies tested were 
able to decrease the binding of the CD23 liposomes, mAb 
25, EBVCS 1, and LA1 mAbs, although directed against three 
different epitopes (17), all inhibited the interaction of CD23 
with its ligand. Isotype-matched controls of IgG1 and IgM 
(data not shown) had no effect. Inhibition was also observed 
with IgE, the other known fig'and for CD23. EBVCS 1, which 
does not inhibit binding of IgE to CD23 (17), was the weakest 
inhibitor of CD23-1iposome binding. 
Since CD23 is a member of CaZ+-dependent lectin family, 
the effect of Ca  2+  on CD23-1iposome binding was inves- 
tigated (Fig.  3). The binding of CD23 liposomes was Ca  2+ 
concentration dependent with a maximum binding of CD23 
liposomes being reached at 2 mM of Ca  2  +. In contrast, the 
binding of protein-flee liposomes was independent of cal- 
cium up to a concentration of 5 raM.  In addition, CD23- 
liposome binding to RPMI 8226 was displaced by 10 mM 
EGTA (85%  inhibition).  These data demonstrate that the 
interaction of CD23 with its ligand is specific and depends 
on the presence of Ca  z  +. 
The Binding  of  CD23 to Its Ligand  Is Decreased  by Tunicamycin 
Treatment and Fucose-l-phosphate.  To determine the potential 
role of oligosaccharides in the interaction with CD23,  the 
effect of tunicamycin, an inhibitor of N-glycosylation, was 
investigated using two ligand-bearing cell lines. Tunicamycin 
treatment of tLPMI 8226 and IM-9 significantly decreased 
the binding of CD23 liposomes, down to the control level 
in the case of IM-9, as shown in Fig. 4.  A pand of sugars 
were then tested for their capacity to inhibit CD23-1iposome 
binding to RPMI 8226 calls.  Fucose-l-phosphate was able 
to prevent CD23-1iposome binding to 1LPMI 8226 calls, as 
shown  in  Fig.  5,  B  and  D.  The  inhibition  by  fucose-1- 
phosphate was concentration dependent with a maximum 
reached  at  12.5  mM  (not  shown).  Glucose-l-phosphate 
(Fig.  5, C  and D) glucose, galactose, mannose, lactose,  N, 
N'-diacetylchitobiose,  cellobiose,  and  mannobiose had  no 
effect. These data suggest a role for a glycan structure con- 
taining, or related to, fucose-l-phosphate type, in the inter- 
action with CD23. 
CD23-transfected  COS Cells  form Conjugates  with the CD23 
Ligand-positive Cell Line, RPMI 8226.  To confirm the ob- 
391  Pochon  et al. Table  1.  Binding  of Recombinant  CD23-incorporated Fluorescent Liposomes to a Panel of Human  Cell Lines 
Origin  Calls"  CD23' 
liposomes 
Control* 
liposomes 
Promydocylic leukemia  HL-60  "  - 
Histiocylic tymphoma  U-937  -  - 
onic. myelogenous  K-562  "  " 
ImmlQ 
T cells 
Leukemia 
Lymphoma 
Tonsil 
.B cells 
mydoma 
EBV-LQ. 
Molt-4 
Hut78 
Jurkat 
E+ 
RPMI 8226 
U266-B1 
U266 
RPMI 8866 
!M-9 
Daudi 
BI.2 
Jijaye 
HFBI WT 
HFBI 2/3 
GCC 
Bu&i, tymphoma 
[ymphoma 
o 
m 
4- 
4"4" 
4"4" 
4" 
+ 
§ 
+/- 
4"  Tonsil 
FACS ~ 
profiles 
E  + 
RPMI 8226 
Non-l~qdlaid 
Umbilical vein 
Astroc,/~0ma 
Epidermaid Carcinoma 
t~nkey k~dney  cells 
HUVECs 
U-373 
~2 
COS 
COS - CD23 
o 
D 
i 
CO5-CD23 
i 
log10 fluorescence 
o_., 
s 
The different cell lines were incubated with CD23 liposomes or control liposomes for 2 h  at 4~  in presence of 2 mM Ca  2+  (detailed in Materials 
and Methods).  After washes,  cells were analyzed by flow cytometry. 
* Cell lines are from human  origin except the COS cells. 
t Results were classified  as no staining  ( -  ),  weak  staining  ( + / -  ),  clear staining  ( + ),  and strong  staining  ( +  + ). 
￿82  Representative staining of cell subpopulations  (E + and GCC),  staining of all cells (R.PMI 8226), and absence of staining (COS-CD23) are shown. 
392  A  New Ligand for CD23 Figure 2.  Inhibition of the binding ofCD23 liposomes 
to KPM18226 by anti-CD23 mAbs and IgE. KPM18226 
cells were incubated with fluorescent CD23 liposomes and 
different anti-CD23 mAbs (30 #g/ml), IgG1 (30 #g/ml) 
as control, or IgE (200 #g/ml) for 2 h at 4~  After two 
washes, cells were analyzed by FACS  O as described in Table 
1. The results of a representative experiment are presented 
and are expressed as a percentage inhibition calculated ac- 
cording to the following formula:  100x  [(MFIcD23 llpo- 
som~) -  (MFIcontml  1i~)1  -  [MFIcDz3  lipomm~*mAb) - 
(MFI~ol ~v=,=,)]/(MI:IcDz~  hwom~ -  MFI~  ~po~m~. 
The MFI of RPM18226 cells in absence of antibody was 
47 arbitrary units (ALl) with CD23 liposomes and 6 AU 
with control liposomes. 
servation made with artificial  membranes in a more natural 
system, we investigated the cellular interaction between COS 
cells expressing CD23 transiently and RPMI 8226.  CD23- 
transfected or mock-transfected COS cells were labeled with 
BCECF and incubated with Indo-l-labeled KPMI 8226 or 
Indo-l-labeled Molt-4 (which do not bind CD23 liposomes). 
As shown in Fig. 6, CD23-transfected COS cells were able 
to bind to RPMI 8226 (Fig.  6 A) but not to Molt-4  (Fig. 
6  C),  confirming  the data obtained with  fluorescent lipo- 
somes. 82% of CD23-positive COS cells were able to form 
conjugates. The interaction of CD23-COS cells with RPMI 
8226 was inhibited by an anti-CD23 mAb (Fig. 6 B), whereas, 
as expected,  this antibody had no effect on the interaction 
between CD23-COS cells and Molt-4 (Fig. 6/9). These results 
demonstrate that recombinant CD23 in cell membranes can 
interact  with  a membrane ligand. 
Discussion 
In this study, the existence of a second ligand for CD23 
is demonstrated.  First, CD23 reconstituted into fluorescent 
liposomes was used to show the presence of a binding struc- 
ture on lymphoid cells by flow cytometric analysis.  Second, 
the demonstration of a ligand for CD23 was not restricted 
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Figure 3.  Effect of Ca  2  + concentration on the binding of CD23 lipo- 
somes to RPMI 8226 cells. RPMI 8226 cells were incubated with CD23 
liposomes or with control liposomes as described in Table 1 in the pres- 
ence of increasing  concentrations  of Ca  2+ . The MFI was measured by 
FACS  | 
Figure 4.  Effect of tunicamycin treatment  on the binding of CD23 lipo- 
somes to CD23 ligand-positive cell lines. RPMI 8226 and IM-9 cell lines 
treated with or without tunicarnycin for 48 h were stained with subop- 
timal concentration of CD23 liposomes or control liposomes  (dilution, 
1/40),  as indicated  in Table 1,  The MFI was measured by FACS  | 
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Figure 5.  Inhibition  of  CD23-1iposome 
binding to  RPMI  8226 cells by fucose-1- 
phosphate. RPMI 8226 cells were incubated 
with CD23 liposomes (CD23-L) or control 
liposomes (ctrl-L) in the presence  of 12.5 mM 
of fucose-l-phosphate (Fuc-P) or ghcose-1- 
phosphate (Glc-P) for 2 h at 4~  After  washes, 
cells were  analyzed  by PACS  O. (.4) RPM18226 
cells were  incubated with CD23 liposomes  and 
control liposomes. B is as A, but in the pres- 
ence of facose-l-phosphate. C is as B, but in 
the presence  of ghcose-l-phosphate. (D) RPMI 
8226 cells  were  incubated  with CD23 liposomes 
in the presence of fucose-l-phosphate  or gh- 
cose-l-phosphate. 
to the use of the reconstituted CD23 since recombinant CD23- 
transfected COS calls were shown to interact specifically with 
the call line RPMI 8226 by forming conjugates. Altogether, 
these two approaches clearly demonstrate the interaction of 
CD23 with a cell surface ligand. 
It is interesting  that  binding  studies using radiolabeled 
purified recombinant and natural soluble CD23 failed to dem- 
onstrate specific binding to any cell types (not shown). Recon- 
stituted full-length CD23 was probably creating a mukivalency 
important  for the interaction  with its ligand. 
Our results on the distribution  of the ligand for CD23 
are in agreement with  the reported biological activities of 
CD23.  RPMI 8866 has been reported to proliferate in re- 
sponse to recombinant CD23 (9), and germinal center B calls 
have been shown to respond to soluble CD23 with IL-1 by 
increased survival (10). Moreover, we show here that a subset 
of T calls also binds the CD23 liposomes. Bertho et al. (25) 
reported the effect of soluble CD23, when added with IL-1, 
on the proliferation of CD4-positive T ceils. We recently also 
found that the membrane form of CD23 was involved in con- 
jugate formation between CD4-positive T  cells and B cells 
(Shields  et al., manuscript  submitted for publication).  Our 
results provide a basis for understanding  how CD23 could 
strongly increase T ceil/B cell cooperation since each cell type 
can express both CD23 and the CD23 ligand. 
The observation that some myeloma cell lines bind CD23 
liposomes needs further investigation to determine whether 
this is linked to any biological effect. The future molecular 
characterization of the CD23-binding structure(s) on various 
cell types will determine if more than one ligand is involved 
in  the CD23  interaction. 
The specificity of the CD23 interaction with a ligand was 
demonstrated.  Liposomes containing  an  unrelated  protein 
(glycophorin), as well as protein-free liposomes, did not bind 
to CD23-binding cell lines. Moreover, the binding of CD23 
liposomes was specifically inhibited by anti-CD23 mAbs and 
IgE but not by isotype-matched controls. 
The CD23 ligand detected here is different from IgE: (a) 
none of the CD23-binding lymphoid cells, except U266-B1, 
expressed detectable IgE on their membranes:  (b) anti-IgE 
antibodies did not inhibit CD23-1iposome binding to U266- 
B1; and (c) the IgE-positive cell line U266 did not bind CD23 
liposomes. Moreover, CD23 does not interact with itself since 
CD23 liposomes did not bind to CD23-transfected COS ceils 
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Figure 6.  COS cells  expressing  recombinant 
membrane  CD23 form  conjugates  with RPMI 
8226 cells. CD23-tramfected  COS cells (28% 
CD23 positive)  and RPM18226 or Molt-4 cells 
were hbded with BCECF-AM  and Indo-l-AM, 
respectively.  After  mixing  and centrifugation, 
ceils were  incubated  for 10 min at 370C. Con- 
jugates are positive  events  for both BCECF  and 
Indo-1 as measured  by FACS  |  The percentage 
of conjugates compared with the number of 
labeled CD23-transfected  COS cells is given. 
(A) CD23-COS cells  were incubated  with con- 
trol IgG1 mAb and then added  to RPM18226 
(23%). B is as A, but CD23-COS cells were 
incubated with mAb 25 anti-CD23 antibody 
(6%). (C) CD23-COS cells were incubated 
with control  IgG1 and then added  to MOLT-4 
cells (2%). D is as C, but CD23-COS cells 
were incubated  with mAb 25 anti-CD23 anti- 
body (2%). 
and no aggregates were observed in the CD23 liposome prepa- 
rations as assessed by photon correlation spectroscopy (data 
not shown). 
Our findings suggest that membrane CD23 should be con- 
sidered as a new adhesion molecule. In fact, CD23 appears 
to be an additional molecule involved in the interaction be- 
tween T and B cells as well as in follicular dendritic cell/ger- 
minal center cell interactions, since follicular dendritic cells 
express high amounts of CD23 (1) and germinal center cells 
bind CD23 liposomes. The existence  of a ligand for CD23 
on some B cells indicates that in addition, CD23 could mediate 
homotypic B cell adhesion. 
In this context, it is interesting to note that CD23 is a 
member  of a  Ca2*-dependent  lectin family (26-28).  We 
demonstrate here that the interaction of CD23 with its ligand 
is Ca  2  + dependent. Some members of this Ca  2  +-dependent 
lectin family have been identified as adhesion molecules, such 
as GMP-140  (29),  MEL-14 (30),  ELAM-1 (31),  and CD72 
(32).  This suggests that CD23 recognizes a sugar structure 
on its ligand. Our finding that tunicamycin treatment of the 
CD23-binding cells decreases the binding of CD23 liposomes 
supports this, although we cannot exclude the possibility that 
tunicamycin affects the intracellular transport and cell sur- 
face expression of the ligand. Moreover, fucose-l-phosphate 
was able to prevent CD23-1iposome binding to its ligand on 
RPMI 8226 cells, suggesting that fucose-l-phosphate, or a 
fucose-like sugar moiety, is involved on the CD23 ligand in 
the interaction with CD23. It is interesting to note that the 
same sugar,  fucose-l-phosphate, has been shown to prevent 
IgE binding to CD23 (33).  Inhibition data with fucose-1- 
phosphate together with our observation that IgE was able 
to prevent CD23 binding to its new ligand on RPMI 8226 
cells suggest that the sites of interaction of CD23 with IgE 
and its other new ligand are close. 
Another feature of human CD23 is the presence of an in- 
verted RGD motif  in its sequence. RGD sequences are known 
to be target sequences for adhesion receptors, and the inverted 
sequence can also play a role (34). However, the importance 
of this sequence needs to be demonstrated since a similar se- 
quence is absent in the mouse CD23 homologue (35,  36), 
and sequences  important for biological function would be 
expected to be conserved. 
In conclusion, CD23, a low affinity receptor for IgE, in- 
teracts with at least two molecules: one is IgE and the other, 
as demonstrated here, is a membrane bound ligand. The latter 
interaction suggests that CD23 can act as an adhesion mole- 
cule enhancing ceU-cell interaction. The identification of the 
ligand for CD23 is currently under investigation. 
395  Pochon  et al. We thank C. Cavegn, S. Henchoz, E. Sebille, and C. Siegfried for their technical assistance, Ms. Leeman 
Husler for the graphics, and Drs.  K. Hardy, J.-J. Mermod, and J. Knowles for their critical review of 
the manuscript. 
Address correspondence to Jean-Yves Bonnefoy, Immunology Section, Ghxo Institute  for Molecular Bi- 
ology S.A.,  14 chemin des Aulx,  1228 Plan-Les-Ouates/Geneva, Switzerland, 
Received for publication  4 March  1992 and in revised form 29 April 1992. 
Note added in proof: We recently identified CD21  as being a ligand for CD23 (37). 
l~rellces 
1.  Gordon, J., L. Flores-Romo, J.A. Cairns, M.J. Millsum, P.J. 
Lane, G.D. Johnson, and I.C.M.  MacLennan.  1989. CD23: 
a  multi-functional  receptor/lymphokine.  Immunol. Today. 
10:153. 
2.  Delespesse, G., M. Sarfati, and H. Hofstetter.  1989. Human 
IgE-binding  factors, lmmunol,  Today. 10:159. 
3.  Conrad, D.H. 1990. FcERII/CD23: the low affinity receptor 
for IgE. Annu. Rev. lmmunol. 8:623. 
4.  Yokota, A., H. Kikutani, T. Tanaka, R. Sato, E.L. Barsumian, 
M. Suemura, and T. Kishimoto.  1988. Two six'des of human 
Fc epsilon receptor II (Fc epsilon RII/CD23): tissue specific 
and Ib4-specific reguhtion of gene expression. Cell. 55:611. 
5.  l~ne, J., F. Rousset,  F. Bri~re, I Chretien, J.Y. Bonnefoy, H. 
Spits, T. Yokota, N. Arai, K.I. Arai, J. Banchereau, and J.E. 
de "Cries. 1988. IgE production by normal human lymphocytes 
is induced by I1r  and suppressed by alpha-interferon, gamma- 
interferon  and prostaglandin  E2. Proa Natl./,cad. Sci. USA. 
85:6880. 
6.  Sarfati, M., E.  Rector,  K.  Wong, M.  Rubio-Trujillo, A.H. 
Sehon, and G. Delespesse. 1984. In vitro synthesis of IgE by 
human lymphocytes. II, Enhancement of the spontaneous IgE 
synthesis by IgE-binding factors secreted by RPMI 8866 lym- 
phoblastoid  B cells. Immunology. 53:197. 
7.  Kehry, M.R.,  and L.C.  Yamashita. 1989. Low-affinity IgE 
receptor  (CD23)  function  on mouse B cells: role  in  IgE- 
dependent antigen focusing. Pag Nail Acad. Sd. USA. 86:7556. 
8.  Gordon, J., J.A. Cairns,  M.J.  Millsum,  S. GiUis, and G.R. 
Guy.  1988. Interlenkin-4  and soluble CD23 as progression 
factors for human B lymphocytes: analysis of their interactions 
with agonists of the phosphoinositide  'dual pathway' of fig- 
nailing. Eur. J. Immunol. 18:1561. 
9. Jansen, K.U., J. Shields, J. Gordon, J. Cairns, P. Graber, and 
J.Y. Bonnefoy. 1991. Expression of human recombinant CD23 
in insect cells, f  Recept. Res. 11:507. 
10.  Lin, Y.J., J.A. Cairns, M.J. Holder, D.S. Abbott, K.U. Jansen, 
J.Y. Bonnefoy, J.  Gordon,  and  I.C.M.  MacLennan. 1991. 
Recombinant  25 kDa CD23 and interleukin-1 alpha promote 
the survival of germinal center cells. Eur.f Immunol. 21:1107. 
11.  Mossalayi, M.D., J.C. Lecron, A.H. Dalloul, M. Sarfati, J.M. 
Bertho,  H.  Hofstetter,  G. Delespesse, and P. Debt6.  1990. 
Soluble CD23 (FcE1LII) and interleukin-1  synergistically in- 
duce early human thymocyte maturation.J.  Ex/~ Med. 171:959. 
12.  Mossalayi, M.D., M. Arock, J.M. Bertho, C. Blanc, A.H. Dal- 
loul, H. Hofstetter,  M. Sarfati, G. Delespesse, and P. Debt6. 
1990. Proliferation of early human myeloid precursors induced 
by interleukin-1 and recombinant soluble CD23. B/ood. 75:1924. 
13.  Flores-Romo, L., G.D. Johnson, A. Veronesi, A. Ghaderi, D.R. 
Stanworth,  and J. Gordon.  1990. Functional implication for 
the topographical association between MHC class II and the 
low affinity IgE receptor: occupancy of CD23 blocks the ability 
of B cells to present alloantigen  to T cells. Fur. J. Immunol. 
20:2465. 
14.  Bonnefoy,  J.-Y., O. Guillot, H. Spits, D. Blanchard, K. Ishizaka, 
and J. Banehereau.  1988. The low affinity receptor  for IgE 
(CD23) on B lymphocytes is spatially associated with HLA- 
DR antigens. J. F.xi~ Med. 176:57. 
15.  Yukawa, K.,  H.  Kikutani,  H.  Howaki,  K.  Yamasaki, A. 
Yokota, H. Nakamura, E.L. Barsumian, R.R. Hardy, M. Sue- 
mura,  and T. Kishimoto.  1987. A B-cell specific differentia- 
tion antigen,  CD23, is a receptor for IgE (Fc epsilon R) on 
lymphocytes. J. Immunol. 38:2576. 
16.  Bonnefoy, J.-Y., J.P. Aubry, C. Peronne, J. Wijdenes, and J. 
Banchereau. 1987. Production and characterization ofa mono- 
clonal antibody specific for the human lymphocyte low affinity 
receptor for IgE: CD23 is a low affinity receptor for IgE. J. 
lmmunol.  138:2970. 
17.  Bonnefoy, J.-Y,, J. Shields, andJ.J. Mermod. 1990. Inhibition 
of human interleukin-4-induced  IgE synthesis by a subset of 
anti-CD23/FcE RII monoclonal antibodies. Fur.  J. Immunol. 
20:139. 
18.  Seed, B., and A. Aruffo. 1987. Molecular cloning of the CD2 
antigen, the T-cell erythrocyte receptor, by a rapid immunoselec- 
tion procedure. Proa Natl. Acad. Sci, USA.  84:3365. 
19.  Lin, Y.J., D.E. Joshua, G.T. Williams, C.A. Smith, J. Gordon, 
and I.C.M.  MacLennan. 1989. Mechanism of antigen-driven 
selection in germinal  centres. Nature (Land.). 342:929. 
20.  Graber, P., K. Jansen, S. Pochon, J. Shields, N. Aubonney, G. 
Tureatti, and J.Y. Bonnefoy. 1992, Purification and character- 
ization of  biologically  active  human recombinant 37 kDa soluble 
CD23/sFcERII expressed in insect cells.J. Immunol. Methods. 
149:215. 
21.  Whelan, J., P. Ghersa, R. Hooft van Huijsduijnen, J. Gray, 
G. Chandra,  F. Talabot, and J. DeLamarter.  1991. An NFK 
B-like factor is essential but not sufficient for cytokine induc- 
tion of endothelial leukocyte adhesion molecule 1 (ELAM-1) 
gene transcription.  Nucleic Acids Res, 19:2645. 
22.  Goff, L.K., R.J. Armitage, and P.C.L. Beverley. 1988. Char- 
acterization of two CD23 monoclonal antibodies with reac- 
tivity distinct  from other antibodies  within this  cluster of 
differentiation.  Immunology. 65:213. 
23.  Kinmer,  C., and B. Sugden. 1981. Identification of antigenic 
determinants  unique  to the surfaces of cells transformed by 
Epstein-Barr virus. Nature (Land.), 294:458. 
24.  Bonnefoy, J.Y., J. Banchereau, J.P. Aubry, and J. Wijdenes. 
1986. A flow cytometric micromethod for the detection of FcE 
receptors and IgE binding  factors using  fluorescent  micro- 
spheres. J. Immunol. Methods. 88:25. 
25.  Bertho, J.M., C. Fourcade, A.H. Dalloul, P. Debt6, and M.D. 
396  A New Ligand for CD23 Mossalayi. 1991. Synergistic  effect  ofinterleukin-1 and soluble 
CD23 on the growth of human CD4 § bone marrow-derived 
T cells. Eur. J. Immunol. 21:1073. 
26.  Kikutani, H., S. Inui, K. Sato, E.L. Barsumian, H. Owaki, 
K. Yamasaki, T. Kaisho, N.  Uchibayashi, R.R.  Hardy, T. 
Hirano,  S.  Tsumasawa, F.  Sakiyama, M.  Suemura, and T. 
Kishimoto. 1986. Molecular structure of human lymphocyte 
receptor for immunoglobulin E. Cell. 47:657. 
27.  Ludin, C., H. Hofstetter, M. Sarfati, C.A. Levy,  U. Suter, D. 
Ahimo, E. Kilcherr, H. Frost, and G. Delespesse. 1987. Cloning 
and expression of the cDNA coding for a human lymphocyte 
IgE receptor. EMBO (Eur. Mol. Biol. Organ.) J. 6:109. 
28.  Ikuta, K., M. Takami, L.W. Kim, T. Honjo, T. Miyoshi, Y. 
Tagaya, T. Kawabe, and J. Yodoi. 1987. Human lymphocyte 
Fc receptor for IgE: sequence homology of its cloned cDNA 
with animal lectins. Pro~ Natl. Acad. Sci. USA.  84:819. 
29. Johnston, G.I., R.G. Cook, and R.P. McEver. 1989. Cloning 
of GMP-140, a granule membrane protein of platdets and en- 
dothelium: sequence similarity  to proteins involved  in cell  adhe- 
sion and inflammation. Cell. 56:1033. 
30. Lasky,  L.A., M.S. Singer, T.A. Yednock, D. Dowbenko, C. 
Fennie, H. Rodriguez, T. Nguyen, S. Stachel, and S.D. Rosen. 
1989. Cloning of a lymphocyte  homing receptor reveals a lectin 
domain. Cell. 56:1055. 
31.  Bevilacqua,  M.P., S. Stengelin, M.A. Gimbrone, and B. Seed. 
1989. Endothdial leukocyte  adhesion molecule 1: an inducible 
receptor for neutrophils related to complement regulatory pro- 
teins and lectins. Science (Wash. DC). 243:1160. 
32.  Van de Velde, H., I. yon Hoegen, W. Luo,  J.R. Parues, and 
K. Thiehmans. 1991. The B-cell surface protein CD72/Lyb-2 
is the ligand for CD5. Nature (Lond.). 351:662. 
33.  Ddespesse, G., M. Sarfati, CX. Wu, S. Fouruier, and M. Letel- 
lier. 1992. The low-affinity receptor for IgE. Immunol. Rev. 
125:77. 
34.  Akiyama, S.K., and K.M. Yamada. 1985. Synthetic peptides 
competitively  inhibit both direct binding to fibrobhst and func- 
tional biological assays for the purified cell binding domain 
of fibronectin, f  Biol. Chem. 260:10402. 
35.  Bettler, B., H. Hofstetter, M. Rao, W.M. Yokoyama,  F. Kilch- 
herr, and D.H. Conrad. 1989. Molecular structure and expres- 
sion of the murine lymphocyte low affinity receptor for IgE 
(FcERII). Pro~ Natl. Acad. Sci. USA.  86:7566. 
36.  GoUnick,  S.O., M.L. Trounstine,  L.C. Yamashita,  M.K. Khery, 
and K.W. Moore. 1990. Isolation, characterization  and expres- 
sion of cDNA dones encoding the mouse Fc receptor for IgE 
(FcERII). f  Immunol. 144:1974. 
37.  Aubry, J.-P.,  S. Pochon, P. Graber, K.U. Jansen, and J.-Y. 
Bonnefoy. 1992. The CR2/EBV receptor, CD21, is a ligand 
for FcER2/CD23, and regulates IgE production. Nature (Lond.). 
In press. 
397  Pochon  et aL 